# Product Summary

| Product Code | Product Name | Modality Name | Product Type | Therapeutic Area | Current Phase | Project Status | Expected Launch Year |
| --- | --- | --- | --- | --- | --- | --- | --- |
| BI 1015550 | Nerandomilast | Small Molecule | NME | Respiratory (IPF; PPF in Zulassung) | Approved/Launched (US, 09-Oct-2025, IPF) | On Track | 2025 |
| BI 1015550_MYO | Nerandomilast | Small Molecule |  | Immunology |  |  | 2030 |
| BI 1015550_PED | Nerandomilast | Small Molecule |  | Respiratory | Pre-Clinical | On Track | 2030 |
| BI 1015550_PPF | Nerandomilast | Small Molecule |  | Respiratory | Phase III | On Track | 2026 |
| BI 1015550_SSC | Nerandomilast | Small Molecule |  | Immunology | Phase II | On Track | 2030 |
| BI 1291583 | Verducatib | Small Molecule | NME | Respiratory; Immunology | Phase III | Delayed | 2029 |
| BI 1291583_PED | Verducatib PED | Small Molecule |  | Respiratory; Immunology | Pre-Clinical |  | 2031 |
| BI 1356225 |  | Small Molecule | NME | Mental Health (Impulsivity in Substance Use Disorder) | Phase I | On Track |  |
| BI 1358894 |  | Small Molecule | NME | Mental Health | Phase II | Discontinued |  |
| BI 1569912 |  | Small Molecule | NME | Mental Health | Phase II | Discontinued |  |
| BI 1584862 | Not disclosed | Small Molecule | NME | Eye Health | Phase II | On Track | 2032 |
| BI 1703880 |  | Small Molecule | NME | Oncology | Phase I | On Track | 2032 |
| BI 1810631 | Zongertinib | Small Molecule | NME | Oncology | Approved/Launched (US, Accelerated Approval 08-Aug-2025) | On Track | 2025 |
| BI 1810631_BC1 | Zongertinib | Small Molecule |  | Oncology |  |  | 2029 |
| BI 1810631_BC2 | Zongertinib | Small Molecule |  | Oncology |  |  | 2032 |
| BI 1810631_GC | Zongertinib | Small Molecule |  | Oncology |  |  | 2031 |
| BI 1810631_NSCLC2 | Zongertinib | Small Molecule |  | Oncology | Phase III |  | 2031 |
| BI 1815368 |  | Small Molecule | NME | Eye Health (DME-Fokus in laufender Entwicklung) | Phase II | On Track | 2032 |
| BI 1815368_NAMD | Not disclosed | Small Molecule |  | Ophthalmology |  |  | 2035 |
| BI 1819479 |  | Small Molecule | NME | Respiratory; Immunology | Phase II | On Track | 2031 |
| BI 1821736 |  | Gene Therapy | NBE | Oncology | Discontinued | Discontinued |  |
| BI 1831169 |  | Gene Therapy | NBE | Oncology | Phase I | On Track | 2034 |
| BI 1839100 |  | Small Molecule | NME | Respiratory | Phase II | On Track |  |
| BI 3000202 |  | Small Molecule | NME | Immunology | Phase I | On Track | 2032 |
| BI 3000202_DF4 | Not disclosed | Small Molecule |  | Immunology / Autoinflammatory Diseases |  |  | 2032 |
| BI 3000202_SSC | Not disclosed | Small Molecule |  | Immunology |  |  | 2035 |
| BI 3006337 | Not disclosed; Partner-Alias: YH25724 | Recombinant Proteins | NBE (Biologic) | Cardiovascular-Renal-Metabolic (CRM) | Discontinued | Discontinued |  |
| BI 3009947 |  | Small Molecule | NME | Immunology | Pre-Clinical | Discontinued |  |
| BI 3018078 / BI 3024308 |  | Gene Therapy | NBE (Biologic) | Oncology | Phase Ib | On Track |  |
| BI 3031185 |  | Small Molecule | NME | Mental Health | Pre-Clinical | On Track | 2034 |
| BI 3032950 |  | Monoclonal Antibody | NBE | Immunology | Phase II | On Track | 2034 |
| BI 3034701 | Not disclosed | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase I | On Track | 2032 |
| BI 3706674 |  | Small Molecule | NME | Oncology | Phase I | On Track |  |
| BI 3720931 |  | Gene Therapy | NBE | Cystic Fibrosis (Respiratory) | Phase I/II (Lenticlair-01 FIH started Nov 2024) | Active | 2032 |
| BI 3731579 |  | Small Molecule | NME | Inflammation & Respiratory / Respiratory (IPF/PPF) | Pre-Clinical | Discontinued | 2033 |
| BI 3776528 |  | Small Molecule | NME | Mental Health – Cognitive impairment in PSD/Schizophrenia | Phase I (laufend) | On Track |  |
| BI 3793898 |  | Small Molecule | NME | Mental Health | Pre-Clinical (post-SoD) | On Track |  |
| BI 3794407 |  | Small Molecule | NME | Inflammation & Respiratory (I&R) | Pre-Clinical | Discontinued |  |
| BI 3797479 |  | Small Molecule | NME | Neuroscience (CIAS – Cognitive Impairment Associated with Schizophrenia) | Preclinical / Early Development |  | 2032 |
| BI 3798489 | BI 3798489 | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Preclinical |  | 2035 |
| BI 3802876 |  | Recombinant Proteins | NBE | Cardiovascular-Renal-Metabolic (CRM) | Phase I (laufend) | On Track |  |
| BI 3804379 |  | Recombinant Proteins | NBE | Cardiovascular-Renal-Metabolic (CRM) | Phase I (laufend) | On Track |  |
| BI 3810477 |  | Monoclonal Antibody | NBE | Inflammation & Respiratory | Phase I | Active | 2034 |
| BI 3810539 |  | Monoclonal Antibody | NBE | Oncology | Discontinued | Discontinued |  |
| BI 3810944 |  | Recombinant Proteins | NBE | Oncology | Phase I | On Track | 2032 |
| BI 3812465 |  | Recombinant Proteins | NBE | Ophthalmology (CI-DME) | Phase I |  | 2032 |
| BI 3814916 | Not yet assigned | Monoclonal Antibody | NBE | Hepatologie (ACLF) | Phase I |  | 2034 |
| BI 3819026 | Anti-LAYN antibody | Monoclonal Antibody | NBE | Oncology | Phase I (FIH) |  | 2026 |
| BI 3820768 |  | T-cell Engager | NBE | Oncology (Solid Tumors) | Preclinical |  | 2031 |
| BI 3821001 | DcR3-Fc | Recombinant Proteins | NBE | Immunology; IBD | Preclinical/SoD (Ende 2024) |  | 2035 |
| BI 3822971 | Not disclosed | T-cell Engager | NBE (ntm) | Oncology | Preclinical |  | 2034 |
| BI 3906517 |  | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Preclinical | On Track |  |
| BI 3907074 / BI 3907075 / BI 3720590 |  | Gene Therapy | NBE | Oncology | Pre-Clinical | On Track | 2034 |
| BI 3923948 | Not disclosed | Gene Therapy | NME | Oncology | Pre-Clinical (IMPD submitted September 2025) | On Track | 2034 |
| BI 3940749 | Not disclosed | Small Molecule | NME | Oncology | Pre-Clinical (FIH Q2/2026) | On Track | 2031 |
| BI 3968621 | Not disclosed | Small Molecule | NME | Oncology | Preclinical |  | 2035 |
| BI 3972080 | CT‑155 | Prescription Digital Therapeutic (SaMD/PDT) | DTx | Mental Health / CNS (CREA) | Phase III – pivotal CONVOKE abgeschlossen; primärer Endpunkt erreicht |  | 2026 |
| BI 4018711 | CT‑156 (working title) | Prescription Digital Therapeutic (SaMD/PDT) | DTx (SaMD) | Schizophrenia / Neuroscience (TA CREA) | Phase II |  | 2028 |
| BI 4041979 | T3P-Y058-739 (Not disclosed) | Gene Therapy | NME | Oncology / Immuno-Oncology | Phase I | On Track | 2032 |
| BI 456906 | Survodutide | Peptides | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase III | Delayed | 2027 |
| BI 456906_GEN2 | Survodutide 2nd Gen | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2029 |
| BI 456906_MASH1 | Survodutide | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) | Phase III | Delayed | 2028 |
| BI 456906_MASH2 | Survodutide | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2030 |
| BI 456906_PED | Survodutide PED | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) | Pre-Clinical |  | 2031 |
| BI 456906_PEN | Survodutide PEN | Peptides |  | Cardiovascular-Renal-Metabolic (CRM) | Development | On Track | 2028 |
| BI 655130 | Spesolimab | Monoclonal Antibody | NBE | Immunology; Neutrophilic Dermatoses | Marketed (GPP flares) |  | 2027 |
| BI 685509 | Avenciguat | Small Molecule | NME | Immunology (Systemische Sklerose) und CRM/Nephrologie (Glomerulonephritiden) | Phase II (SSc) and Phase III (GN) | On Track | 2028 |
| BI 685509_PED | Avenciguat PED | Small Molecule |  | Immunology | Pre-Clinical |  | 2034 |
| BI 685509_SSC | Avenciguat | Small Molecule |  | Immunology | Phase II | On Track | 2030 |
| BI 690517 | Vicadrostat | Small Molecule | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase III | On Track | 2028 |
| BI 690517_CVRR | Vicadrostat + empagliflozin | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2031 |
| BI 690517_HFPEF | Vicadrostat + empagliflozin | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) | Phase III | On Track | 2029 |
| BI 690517_HFREF | Vicadrostat + empagliflozin | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) |  |  | 2030 |
| BI 690517_PED | Vicadrostat + empagliflozin PED | Small Molecule |  | Cardiovascular-Renal-Metabolic (CRM) | Pre-Clinical |  | 2035 |
| BI 706321 |  | Small Molecule | NME | Immunology | Discontinued | Discontinued |  |
| BI 754091 | Ezabenlimab | Monoclonal Antibody | NBE | Oncology | Phase I/II (laufende Kombinationsprogramme) | On Track |  |
| BI 754132 | Not disclosed | Small Molecule | NME | Eye Health | Discontinued | Discontinued |  |
| BI 764198 | Not disclosed | Small Molecule | NME | Nephrology / Renal | Phase II | On Track | 2031 |
| BI 764198_DMD | Not disclosed | Small Molecule |  | Neuromuscular Disorders |  |  | 2032 |
| BI 764198_PED | Not disclosed | Small Molecule |  | Nephrology / Renal | Pre-Clinical |  | 2035 |
| BI 764198_PODO | Not disclosed | Small Molecule |  | Nephrology / Renal |  |  | 2034 |
| BI 764524 | Not disclosed | Monoclonal Antibody | NME | Ophthalmology | Phase II | On Track | 2031 |
| BI 764524_DME | Not disclosed | Monoclonal Antibody |  | Ophthalmology |  |  | 2032 |
| BI 764524_IRVO | Not disclosed | Monoclonal Antibody |  | Ophthalmology |  |  | 2032 |
| BI 764532 | Obrixtamig | T-cell Engager | NME | Oncology | Phase II | On Track | 2027 |
| BI 764532_EPNEC | Obrixtamig | T-cell Engager |  | Oncology | Phase Ib/III | On Track | 2029 |
| BI 764532_SCLC | Obrixtamig | T-cell Engager |  | Oncology | Phase III | On Track | 2029 |
| BI 765049 | Not disclosed | T-cell Engager | NME | Oncology | Phase I | On Track | 2030 |
| BI 765128 |  | Monoclonal Antibody | NBE | Eye Health | Phase I/II (PARTRIDGE 1451-0001) | Discontinued | 2030 |
| BI 765179 | Not disclosed | Monoclonal Antibody | NME | Oncology | Phase Ib | On Track | 2031 |
| BI 765243 |  | Recombinant Proteins | NBE | Eye Health | Pre-Clinical | Discontinued |  |
| BI 765250 |  | Monoclonal Antibody | NBE | Immunology | Phase I (SRD abgeschlossen; MRD laufend/PoCP-Vorbereitung) | On Track |  |
| BI 765423 |  | Monoclonal Antibody | NBE | Respiratory | Phase I | On Track | 2034 |
| BI 765845 | Not disclosed (internal: G5 MYDGF) | Recombinant Proteins | NME | Cardiovascular-Renal-Metabolic (CRM) | Phase II | On Track | 2031 |
| BI 770371 | Not disclosed | Recombinant Proteins | NME | Oncology | Phase I/II | On Track | 2032 |
| BI 770371_MASH | Not disclosed | Recombinant Proteins |  | Hepatology / CRM |  |  | 2034 |
| BI 771716 | Not disclosed | Monoclonal Antibody | NME | Ophthalmology / Retinal Health | Phase II | On Track | 2030 |
| BI XXXXX | Tenecteplase | Recombinant Proteins | NME | Neurology / Stroke | Phase III | On Track | 2029 |
